Tech Could Disrupt Gold Mining
How is this technology going to change the gold mining industry?

NASDAQ:ARDX - Ardelyx Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $7.46
  • Forecasted Upside: 366.41 %
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$1.60
▼ -0.04 (-2.44%)

This chart shows the closing price for ARDX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Ardelyx Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ARDX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ARDX

Analyst Price Target is $7.46
▲ +366.41% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Ardelyx in the last 3 months. The average price target is $7.46, with a high forecast of $15.00 and a low forecast of $2.00. The average price target represents a 366.41% upside from the last price of $1.60.

This chart shows the closing price for ARDX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart
Tech Could Disrupt Gold Mining
How is this technology going to change the gold mining industry?

Current Consensus is Buy

The current consensus among 8 investment analysts is to buy stock in Ardelyx. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/11/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/11/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/9/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/7/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/5/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/6/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/5/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 0 sell ratings
8/4/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/30/2021Cantor FitzgeraldLower Price TargetOverweight$14.00 ➝ $7.00High
7/21/2021CitigroupLower Price TargetBuy$16.00 ➝ $7.00Low
7/21/2021Jefferies Financial GroupDowngradeBuy ➝ Hold$11.00 ➝ $2.00Medium
7/20/2021LADENBURG THALM/SH SHBoost Price TargetBuy$6.50 ➝ $15.00N/A
7/20/2021WedbushDowngradeOutperform ➝ Neutral$3.00N/A
7/20/2021Piper SandlerDowngradeOverweight ➝ Neutral$14.00 ➝ $4.00N/A
7/20/2021CowenSet Price TargetBuy$7.70N/A
3/22/2021WedbushInitiated CoverageOutperform$14.00High
1/5/2021Cantor FitzgeraldInitiated CoverageOverweight$14.00N/A
12/11/2020SVB LeerinkBoost Price TargetPositive ➝ Outperform$11.00 ➝ $14.00High
6/17/2020CowenReiterated RatingBuyMedium
2/18/2020Jefferies Financial GroupReiterated RatingBuy$11.00High
2/12/2020CitigroupInitiated CoverageBuy$13.00 ➝ $13.00Medium
2/10/2020CowenInitiated CoverageOutperformHigh
12/3/2019Jefferies Financial GroupBoost Price TargetBuy$6.00 ➝ $11.00High
10/17/2019Piper Jaffray CompaniesSet Price TargetBuy$15.00High
9/24/2019SVB LeerinkSet Price TargetBuy$9.00Low
9/12/2019Piper Jaffray CompaniesSet Price TargetBuy$15.00High
9/3/2019Piper Jaffray CompaniesSet Price TargetBuy$15.00Low
4/8/2019Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$15.00High
8/24/2018Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$7.00High
8/9/2018CitigroupLower Price TargetBuy ➝ Buy$17.00 ➝ $11.00High
3/19/2018SVB LeerinkReiterated RatingOutperform ➝ Outperform$13.00Medium
3/17/2018Cantor FitzgeraldSet Price TargetBuy$12.00Medium
3/15/2018WedbushReiterated RatingOutperformMedium
2/12/2018Cantor FitzgeraldSet Price TargetBuy$12.00High
1/3/2018Cantor FitzgeraldSet Price TargetBuy$12.00Medium
11/29/2017CitigroupBoost Price TargetBuy ➝ Buy$16.00 ➝ $17.00Low
11/28/2017WedbushReiterated RatingOutperform$13.00 ➝ $12.00Low
11/28/2017Cantor FitzgeraldSet Price TargetBuy$12.00High
11/22/2017LADENBURG THALM/SH SHLower Price TargetBuy ➝ Buy$19.00 ➝ $16.00N/A
11/21/2017Cantor FitzgeraldReiterated RatingBuy$12.00N/A
10/17/2017SVB LeerinkReiterated RatingOutperform$13.00N/A
10/12/2017CitigroupBoost Price TargetBuy$14.00 ➝ $19.00N/A
10/12/2017Cantor FitzgeraldBoost Price TargetOverweight$12.00 ➝ $14.00N/A
10/11/2017Cantor FitzgeraldSet Price TargetBuy$12.00N/A
8/28/2017Cantor FitzgeraldReiterated RatingBuyLow
8/9/2017Cantor FitzgeraldSet Price TargetBuy$12.00High
5/31/2017Cantor FitzgeraldReiterated RatingBuy$12.00Low
5/23/2017BTIG ResearchLower Price TargetBuy$18.00 ➝ $12.00High
5/19/2017Cantor FitzgeraldReiterated RatingOverweight$19.00 ➝ $12.00Low
5/15/2017CitigroupReiterated RatingBuy$17.00 ➝ $12.00Medium
2/15/2017WedbushReiterated RatingOutperform$24.00N/A
1/6/2017WedbushReiterated RatingOutperform$24.00N/A
11/20/2016SVB LeerinkSet Price TargetBuy$18.00N/A
11/8/2016WedbushReiterated RatingOutperform$24.00N/A
8/10/2016CitigroupLower Price TargetBuy$14.00 ➝ $13.00N/A
(Data available from 8/5/2016 forward)
Ardelyx logo
Ardelyx, Inc., a biopharmaceutical company, develops and sells medicines for the treatment of kidney and cardiorenal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase 3 clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase 3 clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program that is in Phase 2 clinical trial for the treatment of patients with hyperkalemia; and RDX020, a small molecule program for the treatment of metabolic acidosis. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Fremont, California.
Read More

Today's Range

Now: $1.60
Low: $1.57
High: $1.69

50 Day Range

MA: $6.11
Low: $1.52
High: $8.17

52 Week Range

Now: $1.60
Low: $1.51
High: $9.23

Volume

10,635,282 shs

Average Volume

24,118,914 shs

Market Capitalization

$157.94 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.85

Frequently Asked Questions

What sell-side analysts currently cover shares of Ardelyx?

The following Wall Street sell-side analysts have issued research reports on Ardelyx in the last year: Cantor Fitzgerald, Citigroup Inc., Cowen Inc, Jefferies Financial Group Inc., LADENBURG THALM/SH SH, Piper Sandler, SVB Leerink LLC, Wedbush, and Zacks Investment Research.
View the latest analyst ratings for ARDX.

What is the current price target for Ardelyx?

8 Wall Street analysts have set twelve-month price targets for Ardelyx in the last year. Their average twelve-month price target is $7.46, suggesting a possible upside of 366.4%. LADENBURG THALM/SH SH has the highest price target set, predicting ARDX will reach $15.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $2.00 for Ardelyx in the next year.
View the latest price targets for ARDX.

What is the current consensus analyst rating for Ardelyx?

Ardelyx currently has 3 hold ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ARDX will outperform the market and that investors should add to their positions of Ardelyx.
View the latest ratings for ARDX.

What other companies compete with Ardelyx?

How do I contact Ardelyx's investor relations team?

Ardelyx's physical mailing address is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. The biopharmaceutical company's listed phone number is 510-745-1700 and its investor relations email address is [email protected] The official website for Ardelyx is www.ardelyx.com.

Tech Could Disrupt Gold Mining
How is this technology going to change the gold mining industry?